Clinical, virological and immunological responses in Danish HIV patients receiving raltegravir as part of a salvage regimen

BACKGROUND: Raltegravir is the first integrase inhibitor approved for treatment of HIV-infected patients harboring multiresistant viruses. METHODS: From a Danish population-based nationwide cohort of HIV patients we identified the individuals who initiated a salvage regimen including raltegravir and...

Descripción completa

Detalles Bibliográficos
Autores principales: Engsig, Frederik N, Gerstoft, Jan, Kronborg, Gitte, Larsen, Carsten S, Pedersen, Gitte, Audelin, Anne M, Jørgensen, Louise B, Obel, Niels
Formato: Texto
Lenguaje:English
Publicado: Dove Medical Press 2010
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2943192/
https://www.ncbi.nlm.nih.gov/pubmed/20865112

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2943192/
https://www.ncbi.nlm.nih.gov/pubmed/20865112

Ejemplares similares